Future prospects for mitosis-targeted antitumor therapies

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Cell cycle dysregulation is a key feature of cancer.
• Targeted antimitotic drugs inhibiting cell cycle proteins have been developed.
• Many novel antimitotic agents failed in clinical trials.

Purpose of the Study:

• To review novel antimitotic drugs targeting cell cycle regulation and mitosis.
• To propose new strategies to enhance the efficacy of these therapies.
• To discuss approaches for future clinical trials.

Main Methods:

• Review of recent advances in antimitotic drug mechanisms.
• Discussion of strategies to increase cell death signals during mitotic arrest.
• Exploration of targeting senescent cells and immunogenic cell death (ICD).

Main Results:

• Several targeted antimitotic drugs have reached clinical trials.
• Most novel antimitotic drug candidates have been discontinued.
• New therapeutic strategies can potentially increase efficacy.

Conclusions:

• Antimitotic therapies targeting cell cycle regulation warrant further investigation.
• Combining antimitotic drugs with strategies to enhance cell death, target senescent cells, or induce ICD may improve outcomes.
• Further clinical trials are needed to validate these enhanced therapeutic approaches for cancer treatment.